ID   SIGL7_HUMAN             Reviewed;         467 AA.
AC   Q9Y286; Q9NZQ1; Q9UJ86; Q9UJ87; Q9Y502;
DT   08-NOV-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1999, sequence version 1.
DT   03-AUG-2022, entry version 190.
DE   RecName: Full=Sialic acid-binding Ig-like lectin 7;
DE            Short=Siglec-7;
DE   AltName: Full=Adhesion inhibitory receptor molecule 1;
DE            Short=AIRM-1;
DE   AltName: Full=CDw328;
DE   AltName: Full=D-siglec;
DE   AltName: Full=QA79 membrane protein;
DE   AltName: Full=p75;
DE   AltName: CD_antigen=CD328;
DE   Flags: Precursor;
GN   Name=SIGLEC7; Synonyms=AIRM1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Dendritic cell;
RX   PubMed=10567377; DOI=10.1074/jbc.274.48.34089;
RA   Nicoll G., Ni J., Liu D., Klenerman P., Munday J., Dubock S., Mattei M.-G.,
RA   Crocker P.R.;
RT   "Identification and characterization of a novel siglec, siglec-7, expressed
RT   by human natural killer cells and monocytes.";
RL   J. Biol. Chem. 274:34089-34095(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3 AND 4), PHOSPHORYLATION, AND
RP   INTERACTION WITH PTPN6.
RC   TISSUE=Lymphoid tissue;
RX   PubMed=10499918; DOI=10.1084/jem.190.6.793;
RA   Falco M., Biassoni R., Bottino C., Vitale M., Sivori S., Augugliaro R.,
RA   Moretta L., Moretta A.;
RT   "Identification and molecular cloning of p75/AIRM1, a novel member of the
RT   sialoadhesin family that functions as an inhibitory receptor in human
RT   natural killer cells.";
RL   J. Exp. Med. 190:793-802(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Dendritic cell;
RA   Zhang W., Wan T., Cao X.;
RT   "Characterization of a novel siglec from dendritic cells.";
RL   Submitted (AUG-1999) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=10764831; DOI=10.1093/glycob/10.4.431;
RA   Angata T., Varki A.;
RT   "Siglec-7: a sialic acid-binding lectin of the immunoglobulin
RT   superfamily.";
RL   Glycobiology 10:431-438(2000).
RN   [5]
RP   FUNCTION.
RX   PubMed=10611343; DOI=10.1073/pnas.96.26.15091;
RA   Vitale C., Romagnani C., Falco M., Ponte M., Vitale M., Moretta A.,
RA   Bacigalupo A., Moretta L., Mingari M.C.;
RT   "Engagement of p75/AIRM1 or CD33 inhibits the proliferation of normal or
RT   leukemic myeloid cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:15091-15096(1999).
RN   [6]
RP   DISIALOGANGLIOSIDE-BINDING.
RX   PubMed=11389909; DOI=10.1016/s0014-5793(01)02476-0;
RA   Ito A., Handa K., Withers D.A., Satoh M., Hakomori S.;
RT   "Binding specificity of siglec7 to disialogangliosides of renal cell
RT   carcinoma: possible role of disialogangliosides in tumor progression.";
RL   FEBS Lett. 498:116-120(2001).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-429, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 18-144, DISULFIDE BOND, AND
RP   GLYCOSYLATION AT ASN-105.
RX   PubMed=12438315; DOI=10.1074/jbc.m210602200;
RA   Alphey M.S., Attrill H., Crocker P.R., van Aalten D.M.;
RT   "High resolution crystal structures of Siglec-7. Insights into ligand
RT   specificity in the Siglec family.";
RL   J. Biol. Chem. 278:3372-3377(2003).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.45 ANGSTROMS) OF 19-150, AND DISULFIDE BOND.
RX   PubMed=14747738; DOI=10.1107/s0907444903028439;
RA   Dimasi N., Moretta A., Moretta L., Biassoni R., Mariuzza R.A.;
RT   "Structure of the saccharide-binding domain of the human natural killer
RT   cell inhibitory receptor p75/AIRM1.";
RL   Acta Crystallogr. D 60:401-403(2004).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 18-144 IN COMPLEX WITH SIALYLATED
RP   LIGAND, GLYCOSYLATION AT ASN-105, AND DISULFIDE BOND.
RX   PubMed=16623661; DOI=10.1042/bj20060103;
RA   Attrill H., Takazawa H., Witt S., Kelm S., Isecke R., Brossmer R., Ando T.,
RA   Ishida H., Kiso M., Crocker P.R., van Aalten D.M.;
RT   "The structure of siglec-7 in complex with sialosides: leads for rational
RT   structure-based inhibitor design.";
RL   Biochem. J. 397:271-278(2006).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 18-144 IN COMPLEX WITH
RP   ALPHA(2,8)-DISIALYLATED LIGAND GT1B, GLYCOSYLATION AT ASN-105, AND
RP   DISULFIDE BOND.
RX   PubMed=16895906; DOI=10.1074/jbc.m601714200;
RA   Attrill H., Imamura A., Sharma R.S., Kiso M., Crocker P.R.,
RA   van Aalten D.M.;
RT   "Siglec-7 undergoes a major conformational change when complexed with the
RT   alpha(2,8)-disialylganglioside GT1b.";
RL   J. Biol. Chem. 281:32774-32783(2006).
RN   [12]
RP   VARIANT [LARGE SCALE ANALYSIS] PRO-215.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Putative adhesion molecule that mediates sialic-acid
CC       dependent binding to cells. Preferentially binds to alpha-2,3- and
CC       alpha-2,6-linked sialic acid. Also binds disialogangliosides
CC       (disialogalactosyl globoside, disialyl lactotetraosylceramide and
CC       disialyl GalNAc lactotetraoslylceramide). The sialic acid recognition
CC       site may be masked by cis interactions with sialic acids on the same
CC       cell surface. In the immune response, may act as an inhibitory receptor
CC       upon ligand induced tyrosine phosphorylation by recruiting cytoplasmic
CC       phosphatase(s) via their SH2 domain(s) that block signal transduction
CC       through dephosphorylation of signaling molecules. Mediates inhibition
CC       of natural killer cells cytotoxicity. May play a role in hemopoiesis.
CC       Inhibits differentiation of CD34+ cell precursors towards
CC       myelomonocytic cell lineage and proliferation of leukemic myeloid cells
CC       (in vitro). {ECO:0000269|PubMed:10611343}.
CC   -!- SUBUNIT: Interacts with PTPN6/SHP-1 upon phosphorylation.
CC       {ECO:0000269|PubMed:10499918, ECO:0000269|PubMed:16623661,
CC       ECO:0000269|PubMed:16895906}.
CC   -!- INTERACTION:
CC       Q9Y286; B2RUZ4: SMIM1; NbExp=3; IntAct=EBI-2801178, EBI-12188413;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=AIRM-1b;
CC         IsoId=Q9Y286-1; Sequence=Displayed;
CC       Name=2; Synonyms=AIRM-2;
CC         IsoId=Q9Y286-2; Sequence=VSP_002555;
CC       Name=3; Synonyms=AIRM-3;
CC         IsoId=Q9Y286-3; Sequence=VSP_002556, VSP_002558;
CC       Name=4;
CC         IsoId=Q9Y286-4; Sequence=VSP_002557, VSP_002558;
CC   -!- TISSUE SPECIFICITY: Predominantly expressed by resting and activated
CC       natural killer cells and at lower levels by granulocytes and monocytes.
CC       High expression found in placenta, liver, lung, spleen, and peripheral
CC       blood leukocytes.
CC   -!- DOMAIN: Contains 1 copy of a cytoplasmic motif that is referred to as
CC       the immunoreceptor tyrosine-based inhibitor motif (ITIM). This motif is
CC       involved in modulation of cellular responses. The phosphorylated ITIM
CC       motif can bind the SH2 domain of several SH2-containing phosphatases.
CC   -!- PTM: Tyrosine phosphorylated. {ECO:0000269|PubMed:10499918}.
CC   -!- MISCELLANEOUS: [Isoform 3]: May be produced at very low levels due to a
CC       premature stop codon in the mRNA, leading to nonsense-mediated mRNA
CC       decay. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the immunoglobulin superfamily. SIGLEC (sialic
CC       acid binding Ig-like lectin) family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAF44346.1; Type=Frameshift; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Functional Glycomics Gateway - Glycan Binding;
CC       Note=Siglec-7;
CC       URL="http://www.functionalglycomics.org/glycomics/GBPServlet?&operationType=view&cbpId=cbp_hum_Itlect_274";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF170485; AAF12759.1; -; mRNA.
DR   EMBL; AJ007395; CAB46011.1; -; mRNA.
DR   EMBL; AJ130710; CAB51126.1; -; mRNA.
DR   EMBL; AJ130711; CAB51127.1; -; mRNA.
DR   EMBL; AJ130712; CAB51128.1; -; mRNA.
DR   EMBL; AJ130713; CAB51129.1; -; mRNA.
DR   EMBL; AF178981; AAF44346.1; ALT_FRAME; mRNA.
DR   EMBL; AF193441; AAF06790.1; -; mRNA.
DR   CCDS; CCDS12826.1; -. [Q9Y286-1]
DR   CCDS; CCDS42601.1; -. [Q9Y286-2]
DR   CCDS; CCDS62771.1; -. [Q9Y286-4]
DR   RefSeq; NP_001264130.1; NM_001277201.1. [Q9Y286-4]
DR   RefSeq; NP_055200.1; NM_014385.3. [Q9Y286-1]
DR   RefSeq; NP_057627.2; NM_016543.3. [Q9Y286-2]
DR   PDB; 1NKO; X-ray; 1.45 A; A=19-150.
DR   PDB; 1O7S; X-ray; 1.75 A; A=18-144.
DR   PDB; 1O7V; X-ray; 1.90 A; A=18-144.
DR   PDB; 2DF3; X-ray; 1.90 A; A=18-144.
DR   PDB; 2G5R; X-ray; 1.60 A; A=18-144.
DR   PDB; 2HRL; X-ray; 1.85 A; A=18-144.
DR   PDBsum; 1NKO; -.
DR   PDBsum; 1O7S; -.
DR   PDBsum; 1O7V; -.
DR   PDBsum; 2DF3; -.
DR   PDBsum; 2G5R; -.
DR   PDBsum; 2HRL; -.
DR   AlphaFoldDB; Q9Y286; -.
DR   SMR; Q9Y286; -.
DR   BioGRID; 117967; 14.
DR   IntAct; Q9Y286; 8.
DR   STRING; 9606.ENSP00000323328; -.
DR   BindingDB; Q9Y286; -.
DR   ChEMBL; CHEMBL3603730; -.
DR   DrugBank; DB03740; N-acetyl-alpha-D-glucosamine.
DR   UniLectin; Q9Y286; -.
DR   GlyConnect; 569; 16 N-Linked glycans.
DR   GlyGen; Q9Y286; 9 sites, 31 N-linked glycans (1 site).
DR   iPTMnet; Q9Y286; -.
DR   PhosphoSitePlus; Q9Y286; -.
DR   BioMuta; SIGLEC7; -.
DR   DMDM; 25009269; -.
DR   jPOST; Q9Y286; -.
DR   MassIVE; Q9Y286; -.
DR   PaxDb; Q9Y286; -.
DR   PeptideAtlas; Q9Y286; -.
DR   PRIDE; Q9Y286; -.
DR   ProteomicsDB; 85695; -. [Q9Y286-1]
DR   ProteomicsDB; 85696; -. [Q9Y286-2]
DR   ProteomicsDB; 85697; -. [Q9Y286-3]
DR   ProteomicsDB; 85698; -. [Q9Y286-4]
DR   Antibodypedia; 18998; 830 antibodies from 35 providers.
DR   CPTC; Q9Y286; 1 antibody.
DR   DNASU; 27036; -.
DR   Ensembl; ENST00000305628.7; ENSP00000306757.6; ENSG00000168995.13. [Q9Y286-2]
DR   Ensembl; ENST00000317643.10; ENSP00000323328.6; ENSG00000168995.13. [Q9Y286-1]
DR   Ensembl; ENST00000536156.5; ENSP00000437609.1; ENSG00000168995.13. [Q9Y286-3]
DR   Ensembl; ENST00000600577.1; ENSP00000472529.1; ENSG00000168995.13. [Q9Y286-4]
DR   GeneID; 27036; -.
DR   KEGG; hsa:27036; -.
DR   MANE-Select; ENST00000317643.10; ENSP00000323328.6; NM_014385.4; NP_055200.1.
DR   UCSC; uc002pvv.1; human. [Q9Y286-1]
DR   CTD; 27036; -.
DR   DisGeNET; 27036; -.
DR   GeneCards; SIGLEC7; -.
DR   HGNC; HGNC:10876; SIGLEC7.
DR   HPA; ENSG00000168995; Tissue enhanced (lymphoid).
DR   MIM; 604410; gene.
DR   neXtProt; NX_Q9Y286; -.
DR   OpenTargets; ENSG00000168995; -.
DR   PharmGKB; PA35777; -.
DR   VEuPathDB; HostDB:ENSG00000168995; -.
DR   eggNOG; ENOG502S41V; Eukaryota.
DR   GeneTree; ENSGT01040000240469; -.
DR   HOGENOM; CLU_024444_6_1_1; -.
DR   InParanoid; Q9Y286; -.
DR   OMA; CFQNLTC; -.
DR   OrthoDB; 324083at2759; -.
DR   PhylomeDB; Q9Y286; -.
DR   TreeFam; TF332441; -.
DR   PathwayCommons; Q9Y286; -.
DR   Reactome; R-HSA-198933; Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell.
DR   SignaLink; Q9Y286; -.
DR   BioGRID-ORCS; 27036; 12 hits in 1071 CRISPR screens.
DR   ChiTaRS; SIGLEC7; human.
DR   EvolutionaryTrace; Q9Y286; -.
DR   GeneWiki; SIGLEC7; -.
DR   GenomeRNAi; 27036; -.
DR   Pharos; Q9Y286; Tchem.
DR   PRO; PR:Q9Y286; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; Q9Y286; protein.
DR   Bgee; ENSG00000168995; Expressed in granulocyte and 129 other tissues.
DR   ExpressionAtlas; Q9Y286; baseline and differential.
DR   Genevisible; Q9Y286; HS.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0030246; F:carbohydrate binding; TAS:ProtInc.
DR   GO; GO:0033691; F:sialic acid binding; IBA:GO_Central.
DR   GO; GO:0038023; F:signaling receptor activity; TAS:ProtInc.
DR   GO; GO:0007155; P:cell adhesion; IBA:GO_Central.
DR   Gene3D; 2.60.40.10; -; 3.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR013106; Ig_V-set.
DR   Pfam; PF13895; Ig_2; 1.
DR   Pfam; PF07686; V-set; 1.
DR   SMART; SM00409; IG; 3.
DR   SMART; SM00408; IGc2; 1.
DR   SUPFAM; SSF48726; SSF48726; 3.
DR   PROSITE; PS50835; IG_LIKE; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell adhesion; Disulfide bond;
KW   Glycoprotein; Immunoglobulin domain; Lectin; Membrane; Phosphoprotein;
KW   Reference proteome; Repeat; Signal; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..18
FT                   /evidence="ECO:0000255"
FT   CHAIN           19..467
FT                   /note="Sialic acid-binding Ig-like lectin 7"
FT                   /id="PRO_0000014947"
FT   TOPO_DOM        19..353
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        354..376
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        377..467
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          39..122
FT                   /note="Ig-like V-type"
FT   DOMAIN          150..233
FT                   /note="Ig-like C2-type 1"
FT   DOMAIN          240..336
FT                   /note="Ig-like C2-type 2"
FT   REGION          401..431
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          443..467
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           435..440
FT                   /note="ITIM motif"
FT   COMPBIAS        415..429
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         124
FT                   /ligand="N-acetylneuraminate"
FT                   /ligand_id="ChEBI:CHEBI:35418"
FT                   /evidence="ECO:0000269|PubMed:16623661,
FT                   ECO:0000269|PubMed:16895906"
FT   BINDING         131..135
FT                   /ligand="N-acetylneuraminate"
FT                   /ligand_id="ChEBI:CHEBI:35418"
FT                   /evidence="ECO:0000269|PubMed:12438315,
FT                   ECO:0000269|PubMed:16623661, ECO:0000269|PubMed:16895906"
FT   MOD_RES         429
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   CARBOHYD        105
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16623661,
FT                   ECO:0000269|PubMed:16895906"
FT   CARBOHYD        142
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        165
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        229
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        235
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        242
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        260
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        334
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        46..106
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:12438315, ECO:0000269|PubMed:14747738,
FT                   ECO:0000269|PubMed:16623661, ECO:0000269|PubMed:16895906"
FT   DISULFID        168..217
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DISULFID        276..320
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   VAR_SEQ         145..238
FT                   /note="ALTHRPNILIPGTLESGCFQNLTCSVPWACEQGTPPMISWMGTSVSPLHPST
FT                   TRSSVLTLIPQPQHHGTSLTCQVTLPGAGVTTNRTIQLNVSY -> D (in isoform
FT                   2)"
FT                   /evidence="ECO:0000303|PubMed:10499918,
FT                   ECO:0000303|PubMed:10764831, ECO:0000303|Ref.3"
FT                   /id="VSP_002555"
FT   VAR_SEQ         145
FT                   /note="A -> E (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:10499918"
FT                   /id="VSP_002556"
FT   VAR_SEQ         145
FT                   /note="A -> G (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:10499918"
FT                   /id="VSP_002557"
FT   VAR_SEQ         146..467
FT                   /note="Missing (in isoform 3 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:10499918"
FT                   /id="VSP_002558"
FT   VARIANT         215
FT                   /note="L -> P (in a colorectal cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_035523"
FT   CONFLICT        42
FT                   /note="V -> A (in Ref. 4; AAF44346)"
FT                   /evidence="ECO:0000305"
FT   HELIX           23..25
FT                   /evidence="ECO:0007829|PDB:1NKO"
FT   STRAND          27..30
FT                   /evidence="ECO:0007829|PDB:1NKO"
FT   STRAND          32..37
FT                   /evidence="ECO:0007829|PDB:1NKO"
FT   STRAND          42..44
FT                   /evidence="ECO:0007829|PDB:1NKO"
FT   STRAND          46..49
FT                   /evidence="ECO:0007829|PDB:1NKO"
FT   TURN            54..58
FT                   /evidence="ECO:0007829|PDB:1NKO"
FT   STRAND          62..67
FT                   /evidence="ECO:0007829|PDB:1NKO"
FT   STRAND          69..71
FT                   /evidence="ECO:0007829|PDB:2HRL"
FT   HELIX           72..74
FT                   /evidence="ECO:0007829|PDB:1O7V"
FT   STRAND          78..81
FT                   /evidence="ECO:0007829|PDB:1NKO"
FT   HELIX           85..88
FT                   /evidence="ECO:0007829|PDB:2HRL"
FT   HELIX           89..91
FT                   /evidence="ECO:0007829|PDB:1NKO"
FT   TURN            92..94
FT                   /evidence="ECO:0007829|PDB:1NKO"
FT   STRAND          95..97
FT                   /evidence="ECO:0007829|PDB:1NKO"
FT   HELIX           101..103
FT                   /evidence="ECO:0007829|PDB:1NKO"
FT   STRAND          108..110
FT                   /evidence="ECO:0007829|PDB:1NKO"
FT   HELIX           115..117
FT                   /evidence="ECO:0007829|PDB:1NKO"
FT   STRAND          119..127
FT                   /evidence="ECO:0007829|PDB:1NKO"
FT   STRAND          130..133
FT                   /evidence="ECO:0007829|PDB:1NKO"
FT   STRAND          139..144
FT                   /evidence="ECO:0007829|PDB:1NKO"
SQ   SEQUENCE   467 AA;  51143 MW;  8AFE44462B001F52 CRC64;
     MLLLLLLPLL WGRERVEGQK SNRKDYSLTM QSSVTVQEGM CVHVRCSFSY PVDSQTDSDP
     VHGYWFRAGN DISWKAPVAT NNPAWAVQEE TRDRFHLLGD PQTKNCTLSI RDARMSDAGR
     YFFRMEKGNI KWNYKYDQLS VNVTALTHRP NILIPGTLES GCFQNLTCSV PWACEQGTPP
     MISWMGTSVS PLHPSTTRSS VLTLIPQPQH HGTSLTCQVT LPGAGVTTNR TIQLNVSYPP
     QNLTVTVFQG EGTASTALGN SSSLSVLEGQ SLRLVCAVDS NPPARLSWTW RSLTLYPSQP
     SNPLVLELQV HLGDEGEFTC RAQNSLGSQH VSLNLSLQQE YTGKMRPVSG VLLGAVGGAG
     ATALVFLSFC VIFIVVRSCR KKSARPAADV GDIGMKDANT IRGSASQGNL TESWADDNPR
     HHGLAAHSSG EEREIQYAPL SFHKGEPQDL SGQEATNNEY SEIKIPK
//
